TRT on TikTok: separating the hype from the hormone data
Quick answer
Low libido in women over 50 is predominantly driven by declining estrogen and testosterone, genitourinary syndrome of menopause, and psychosocial factors, none of which are meaningfully addressed by acupressure alone. The creator targets a real and underserved population but bypasses evidence-based options including low-dose testosterone therapy, which has robust RCT support for improving sexual desire in postmenopausal women. Acupressure at the specific points described has limited low-certainty evidence for subjective sexual function improvement, but has not been shown to alter uterine or ovarian blood flow as claimed.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @jimmyacusensei actually say?
The creator claimed that pressing three specific foot points, between the first and second toes, near the Achilles tendon at the ankle, and along the heel, for 30 seconds each, twice daily, will "guide blood to your uterus and your ovaries" and "increase that libido" in women in their 50s and 60s. No qualifications, no caveats, no mention of what actually drives low libido at that life stage.
To be fair, the creator is pointing to areas that loosely correspond to classical acupressure points. The first web space of the foot is near Liver 3 (Taichong) in traditional Chinese medicine. The medial ankle region corresponds to Kidney 3 and Spleen 6, points historically used in TCM for reproductive complaints. So this isn't random button-mashing. It's a real tradition. The question is whether that tradition holds up when you put it in front of a randomized controlled trial.
Does the science back this up?
The honest answer is: weakly, and not specifically for libido. There is some low-quality evidence that acupressure and acupuncture may improve self-reported sexual function in perimenopausal and postmenopausal women, but the effect sizes are modest and the studies are riddled with methodological problems.
A 2021 systematic review by Ee et al. in Menopause looked at acupuncture and acupressure for menopause symptoms and found limited, low-certainty evidence for improvements in quality of life and some vasomotor symptoms. Sexual function was a secondary outcome at best. A 2019 study by Salehi et al. in Complementary Therapies in Clinical Practice found acupressure at Spleen 6 improved sexual function scores in postmenopausal women compared to sham, but the sample was small (n=60) and the outcome measure was self-reported. That is not nothing, but it is a long way from a confident clinical recommendation.
The claim that pressing your foot will literally "guide blood to your uterus" is not supported by vascular physiology. Uterine and ovarian blood flow is regulated by hormones, autonomic tone, and local vasodilatory signals, not reflexology maps.
What did they get wrong (or right)?
What they got wrong, and it matters: the creator skips entirely over why libido declines in women in their 50s and 60s. The dominant drivers are estrogen decline, testosterone decline (yes, women have testosterone too), genitourinary syndrome of menopause, sleep disruption, mood disorders, and relationship factors. A 2019 review by Islam et al. in Sexual Medicine Reviews laid this out clearly. None of those causes respond to foot massage.
The "get the juices flowing" framing is also a problem. It implies a hydraulic model of arousal that oversimplifies female sexual response considerably. It also sidesteps the fact that for many women in this age group, low libido is a symptom with identifiable hormonal causes that respond to evidence-based treatments.
What they got partially right: the specific points named are at least consistent with TCM tradition rather than invented. And recommending a low-risk daily self-care practice is not dangerous. It just should not be presented as a standalone solution for a condition with real clinical underpinnings.
What should you actually know?
Low libido in postmenopausal women is a legitimate medical concern with a clinical name: hypoactive sexual desire disorder (HSDD). The FDA has approved treatments for it. Flibanserin is approved for premenopausal women. For postmenopausal women, off-label low-dose testosterone therapy has the strongest evidence base for improving sexual desire, supported by multiple RCTs including the large Intrinsa trials and summarized in the 2019 Global Consensus Position Statement on testosterone use in women published in The Journal of Clinical Endocrinology and Metabolism.
Acupressure as an adjunct, meaning alongside real evaluation and treatment, is unlikely to cause harm and may provide some subjective benefit. As a replacement for addressing hormonal deficiency, it falls short. If you are a woman in your 50s or 60s dealing with low libido and it is affecting your quality of life, that is worth a conversation with a clinician who can actually assess your hormone levels and rule out treatable causes.
Pressing your heel for 30 seconds is not a clinical intervention. It is not wrong to try. It is wrong to stop there.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For TRT on TikTok: separating the hype from the hormone data, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Understanding weight gain at menopause
Background source for body-composition and weight-change discussions around menopause.
PubMed
Management of obesity in menopause
Current source for menopause-specific obesity management framing.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
TRT on TikTok: separating the hype from the hormone data should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
Low libido in women over 50 is predominantly driven by declining estrogen and testosterone, genitourinary syndrome of menopause, and psychosocial factors, none of which are meaningfully addressed by acupressure alone.
FormBlends verdict
Low libido in women over 50 is predominantly driven by declining estrogen and testosterone, genitourinary syndrome of menopause, and psychosocial factors, none of which are meaningfully addressed by acupressure alone. The creator targets a real and underserved population but bypasses evidence-based options including low-dose testosterone therapy, which has robust RCT support for improving sexual desire in postmenopausal women. Acupressure at the specific points described has limited low-certainty evidence for subjective sexual function improvement, but has not been shown to alter uterine or ovarian blood flow as claimed.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Low libido in women over 50 is predominantly driven by declining estrogen and testosterone, genitourinary syndrome of menopause, and psychosocial factors, none of which are meaningfully addressed by acupressure alone. The creator targets a real and underserved population but bypasses evidence-based options including low-dose testosterone therapy, which has robust RCT support for improving sexual desire in postmenopausal women. Acupressure at the specific points described has limited low-certainty evidence for subjective sexual function improvement, but has not been shown to alter uterine or ovarian blood flow as claimed.
- Hypoactive sexual desire disorder (HSDD) affects an estimated 10-40% of postmenopausal women and has identifiable hormonal causes that respond to evidence-based treatments.
- A 2019 Global Consensus Position Statement in the Journal of Clinical Endocrinology and Metabolism found low-dose testosterone therapy has the strongest RCT evidence for improving sexual desire in postmenopausal women.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Hypoactive sexual desire disorder (HSDD) affects an estimated 10-40% of postmenopausal women and has identifiable hormonal causes that respond to evidence-based treatments.
- A 2019 Global Consensus Position Statement in the Journal of Clinical Endocrinology and Metabolism found low-dose testosterone therapy has the strongest RCT evidence for improving sexual desire in postmenopausal women.
- Salehi et al. (2019) found acupressure at Spleen 6 improved sexual function scores versus sham in a 60-person RCT, but the study was small and outcomes were self-reported.
- A 2021 systematic review in Menopause (Ee et al.) rated evidence for acupressure and menopause symptoms as low certainty, with sexual function as a secondary outcome.
- There is no published vascular physiology evidence that foot acupressure redirects blood flow to the uterus or ovaries as the creator claims.
- Acupressure at the described points carries essentially no harm risk and may provide subjective benefit, but it should not substitute for clinical evaluation of hormonal status.
- Women in their 50s and 60s with persistent low libido that affects quality of life should seek evaluation of estrogen, testosterone, and thyroid levels before assuming lifestyle measures are sufficient.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
jimmyacusensei · TikTok creator
249.9K views on this video
TRT on TikTok: separating the hype from the hormone data
Not medical advice. This video was made by jimmyacusensei, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.